AdaptHealth (AHCO) Q4 2024 earnings summary

Executive summary

• Full year 2024 net revenue grew 1.9% year-over-year to $3.26 billion, overcoming headwinds from asset divestitures and reimbursement changes; net income was $90.4 million, reversing a $678.9 million loss in 2023.

• Adjusted EBITDA rose 2.7% to $688.7 million for the year; free cash flow improved to $235.8 million from $143.2 million.

• Q4 2024 revenue was flat year-over-year but 3% above guidance midpoint; Sleep Health and Respiratory Health grew, offsetting Diabetes Health contraction.

• Strategic focus areas included operational excellence, AI and automation, clinical relevance, organic growth, and balance sheet strength.

• Leadership changes and organizational restructuring were implemented to drive accountability and segment performance.

Financial highlights

• Full-year operating income was $263.7 million, up from a loss of $598.4 million in 2023.

• Q4 Adjusted EBITDA margin was 23.4%, slightly down from 23.8% in Q4 2023; full-year margin was 21.1%.

• Q4 free cash flow was $73.1 million, up 10% year-over-year and above guidance.

• Goodwill impairment charges were $13.1 million in 2024, significantly lower than $830.8 million in 2023.

• Cash flow from operations for 2024 was $541.8 million, up from $480.7 million.

Outlook and guidance

• 2025 revenue guidance: $3.22–$3.36 billion (–1% to +3% growth), reflecting asset dispositions and revenue mix changes.

• 2025 Adjusted EBITDA expected at $670–$710 million (~21% margin), in line with 2024.

• 2025 free cash flow guidance: $180–$220 million, with one-third expected in H1.

• Q1 2025 revenue expected down 3–4% year-over-year; Adjusted EBITDA margin 16–17%.

• Guidance excludes impact from future acquisitions or dispositions not yet closed.